SCHEMBL1148664

SCHEMBL1148664

COc1c(-c2cc(C(=O)Nc3cccc(C(F)(F)F)c3)ccc2C)cc2cnc(NC(C)C)nc2c1Br

nearest known ligand 0.53

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
LCK P06239 11/20 0.53
MAPK14 Q16539 9/20 0.53
KDR P35968 8/20 0.53
BRAF P15056 5/20 0.53
JAK3 P52333 4/20 0.53
TEK Q02763 2/20 0.53
DDR2 Q16832 3/20 0.49
KIT P10721 4/20 0.48
SYK P43405 2/20 0.48
BTK Q06187 3/20 0.46
DDR1 Q08345 1/20 0.46
RAF1 P04049 2/20 0.45
SRC P12931 3/20 0.45
TYK2 P29597 1/20 0.45
MAPK8 P45983 1/20 0.45
MAPK9 P45984 1/20 0.45
MAPK10 P53779 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1149165 0.92 LCK (0.64) LCKMAPK14KDRBRAFJAK3
SCHEMBL1078471 0.88 BRAF (0.44) LCKMAPK14KDRBRAFJAK3
SCHEMBL1149502 0.88 LCK (0.50) LCKMAPK14KDRBRAFJAK3
SCHEMBL1079016 0.86 DDR2 (0.57) LCKMAPK14KDRBRAFJAK3
SCHEMBL1079493 0.85 LCK (0.53) LCKMAPK14KDRBRAFJAK3
SCHEMBL1079473 0.84 RAF1 (0.37) LCKMAPK14KDRBRAFJAK3
SCHEMBL1078341 0.82 LCK (0.70) LCKMAPK14KDRBRAFJAK3
SCHEMBL1076599 0.82 BRAF (0.44) LCKMAPK14KDRBRAFJAK3
SCHEMBL1078714 0.82 LCK (0.63) LCKMAPK14KDRBRAFJAK3
SCHEMBL1048299 0.81 CSNK2A1 (0.42) MAPK14

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110039845-A1 2-AMINOQUINAZOLINE DERIVATIVE KYOWA HAKKO KIRIN CO., LTD. (JP) 2011-02-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110039845-A1 2-AMINOQUINAZOLINE DERIVATIVE H1-2, H1-3, H1-0 LCK 3187/4885MAPK14 2338/4885KDR 896/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.